ATE361075T1 - Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung - Google Patents

Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung

Info

Publication number
ATE361075T1
ATE361075T1 AT03725053T AT03725053T ATE361075T1 AT E361075 T1 ATE361075 T1 AT E361075T1 AT 03725053 T AT03725053 T AT 03725053T AT 03725053 T AT03725053 T AT 03725053T AT E361075 T1 ATE361075 T1 AT E361075T1
Authority
AT
Austria
Prior art keywords
long
pharmaceutical combination
benigan
treatment
urinary retention
Prior art date
Application number
AT03725053T
Other languages
English (en)
Inventor
Wolfgang Baiker
Ludwig Mehlburger
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29271571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE361075(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2002118392 external-priority patent/DE10218392A1/de
Priority claimed from DE2002118611 external-priority patent/DE10218611A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE361075T1 publication Critical patent/ATE361075T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
AT03725053T 2002-04-24 2003-04-17 Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung ATE361075T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002118392 DE10218392A1 (de) 2002-04-24 2002-04-24 Verwendung von Arzneimittelkombinationen zur Behandlung von benigner Prostatahyperplasie
DE2002118611 DE10218611A1 (de) 2002-04-25 2002-04-25 Verwendung einer Tamsulosin enthaltenden Arzneimittelkombination zur Behandlung von benigner Prostatahyperplasie

Publications (1)

Publication Number Publication Date
ATE361075T1 true ATE361075T1 (de) 2007-05-15

Family

ID=29271571

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725053T ATE361075T1 (de) 2002-04-24 2003-04-17 Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung

Country Status (22)

Country Link
US (2) US20030225118A1 (de)
EP (2) EP1501517B1 (de)
JP (1) JP2005524693A (de)
CN (1) CN1646135A (de)
AT (1) ATE361075T1 (de)
AU (1) AU2003227643A1 (de)
BR (1) BR0309435A (de)
CA (1) CA2479992A1 (de)
CY (1) CY1107674T1 (de)
DE (1) DE60313603T2 (de)
DK (1) DK1501517T3 (de)
EA (1) EA008377B1 (de)
ES (1) ES2287474T3 (de)
HR (1) HRP20040994A2 (de)
IL (1) IL163976A0 (de)
MX (1) MXPA04010408A (de)
NO (1) NO20044333L (de)
NZ (1) NZ536514A (de)
PL (1) PL371430A1 (de)
PT (1) PT1501517E (de)
RS (1) RS92304A (de)
WO (1) WO2003090753A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287474T3 (es) * 2002-04-24 2007-12-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Combinacion farmaceutica para el tratamiento de la hiperplasia prostatica benigna o para la prevencion a la largo plazo de la retencion urinaria aguda.
WO2005042021A2 (de) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
CN101452893B (zh) * 2003-11-14 2011-04-13 株式会社半导体能源研究所 显示装置及其制造法
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
CN102309495A (zh) * 2010-06-30 2012-01-11 北京润德康医药技术有限公司 一种复方制剂及其制备方法
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
WO2012162776A1 (pt) * 2011-06-03 2012-12-06 Eurofarma Laboratórios S.A Composição farmacêutica para o tratamento de hiperplasia prostática benigna
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
BR102013020508B1 (pt) * 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
AU2016331879A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
CN115969860A (zh) * 2021-10-14 2023-04-18 上海汇伦医药股份有限公司 一种药物组合物及其用途
CN119278030A (zh) * 2023-04-13 2025-01-07 上海汇伦医药股份有限公司 一种双重释放制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
US4760071A (en) 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
DE3888994T2 (de) 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
DE3888378T2 (de) 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
TW369521B (en) 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW382595B (en) 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US6423719B1 (en) * 1999-02-16 2002-07-23 Upsher-Smith Laboratories, Inc. Method for treating benign prostate hyperplasia
WO2001021167A1 (en) * 1999-09-22 2001-03-29 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein
ES2287474T3 (es) * 2002-04-24 2007-12-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Combinacion farmaceutica para el tratamiento de la hiperplasia prostatica benigna o para la prevencion a la largo plazo de la retencion urinaria aguda.

Also Published As

Publication number Publication date
WO2003090753A8 (en) 2004-11-04
WO2003090753A1 (en) 2003-11-06
MXPA04010408A (es) 2005-02-17
EP1743656A3 (de) 2007-03-07
NZ536514A (en) 2006-11-30
PL371430A1 (en) 2005-06-13
US20030225118A1 (en) 2003-12-04
AU2003227643A1 (en) 2003-11-10
EP1743656A2 (de) 2007-01-17
DE60313603D1 (de) 2007-06-14
US20070197666A1 (en) 2007-08-23
EP1501517A1 (de) 2005-02-02
ES2287474T3 (es) 2007-12-16
PT1501517E (pt) 2007-05-31
HRP20040994A2 (en) 2005-02-28
RS92304A (sr) 2006-10-27
NO20044333L (no) 2004-11-09
CA2479992A1 (en) 2003-11-06
EA200401340A1 (ru) 2005-06-30
CY1107674T1 (el) 2013-04-18
EP1501517B1 (de) 2007-05-02
CN1646135A (zh) 2005-07-27
JP2005524693A (ja) 2005-08-18
DK1501517T3 (da) 2007-06-11
BR0309435A (pt) 2005-02-15
IL163976A0 (en) 2005-12-18
DE60313603T2 (de) 2008-01-03
EA008377B1 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
DE60313603D1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
ATE242238T1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE69921852D1 (de) Kombinationstherapie enthaltend bestrahlung und einen cox-2 hemmer in der behandlung von neoplasie
EP1320376A4 (de) Behandlung von prostatakrebs
DK1368054T3 (da) Anvendelse af neurale trådproteiner til behandling af tumorer
EP1592430A4 (de) Behandlung gutartiger prostatahyperplasie mittels energolytischer wirkstoffe
EP1441761A4 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
ATE337005T1 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
ATE250580T1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
GB0301016D0 (en) Treatment of benign prostatic hyperplasia
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
ECSP982362A (es) Compuestos de quinolina y quinazolina utiles en terapia
ATE222263T1 (de) Prostata-spezifische antigen inhibitore

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1501517

Country of ref document: EP